GLP-1s and Kidney Health

Chronic kidney disease (CKD) affects a significant proportion of people with type 2 diabetes. In 2025, semaglutide received FDA approval to reduce the risk of kidney disease progression in adults with type 2 diabetes and CKD, based on the FLOW trial. Here's what the evidence shows.

What is the link between type 2 diabetes and CKD?

Chronic kidney disease is one of the most common complications of type 2 diabetes. Persistently elevated blood sugar damages the blood vessels in the kidneys over time — a process called diabetic nephropathy. This leads to progressive loss of kidney function, measured by declining glomerular filtration rate (GFR) and increasing urinary albumin (protein in the urine).

People with type 2 diabetes are at significantly elevated risk of developing CKD, and CKD in turn raises the risk of cardiovascular events, kidney failure, and the need for dialysis. Managing blood sugar and blood pressure are central to slowing CKD progression in this population — and emerging evidence suggests that GLP-1 medications may add to these benefits.

What did the FLOW trial show?

The FLOW trial enrolled adults with type 2 diabetes and chronic kidney disease. Participants were randomly assigned to receive semaglutide or placebo, in addition to their usual care.

The trial showed a clinically meaningful reduction in kidney disease progression events in participants treated with semaglutide, compared to placebo. The results were significant enough that the trial was stopped early — an indicator that the benefit was considered sufficiently clear.

The FLOW trial provided the specific evidence base that supported the 2025 FDA approval of semaglutide for kidney disease progression in adults with type 2 diabetes and CKD.

What does the 2025 kidney approval cover?

The 2025 approval is specifically for:

• Adults with type 2 diabetes
• Who also have chronic kidney disease
• To reduce the risk of kidney disease progression, kidney failure, and cardiovascular events in this population

This is a separate indication from the existing type 2 diabetes management approval for Ozempic. The prescribing information and clinical context differs, and a nephrologist or clinician experienced in CKD management would typically be involved in treatment decisions.

Does this mean GLP-1s protect the kidneys generally?

No. The 2025 approval applies specifically to adults with type 2 diabetes and CKD. It does not establish that GLP-1 medications protect kidney function in people without type 2 diabetes, or in people with kidney disease from other causes.

Kidney function also matters for how medications are dosed and tolerated. For people with significant CKD, drug dosing often requires adjustment — your prescribing clinician assesses this as part of the consultation. Do not adjust dosing yourself based on your kidney function.

If you have type 2 diabetes and have been told you have reduced kidney function, this is a conversation to have with your clinician. The FLOW trial results and the new approval may be relevant to your care plan.

Frequently asked questions

Can anyone with CKD use semaglutide for kidney protection?
The 2025 approval is specifically for adults with type 2 diabetes and CKD. People with CKD but without type 2 diabetes are not covered by this specific approval. Speak to your clinician about what's appropriate.

I'm already on Ozempic for diabetes — does this approval apply to me?
If you also have CKD, the kidney-protective indication may be relevant to your treatment plan. This is a conversation to have with your clinician or nephrologist.

Do GLP-1 medications require dose adjustment in kidney disease?
Kidney function can affect how medications are processed. Your prescribing clinician checks renal function as part of assessment — do not adjust dosing yourself.

Are there other medications used to protect kidneys in T2D?
Yes — SGLT2 inhibitors (like empagliflozin) also have kidney-protective approvals. GLP-1s and SGLT2 inhibitors are sometimes used together. This is a clinical decision.